WO2002016431A2 - PEPTIDE DES α1-ADRENERGEN REZEPTORS UND IHRE VERWENDUNG BEI PSORIASIS - Google Patents
PEPTIDE DES α1-ADRENERGEN REZEPTORS UND IHRE VERWENDUNG BEI PSORIASIS Download PDFInfo
- Publication number
- WO2002016431A2 WO2002016431A2 PCT/DE2001/003140 DE0103140W WO0216431A2 WO 2002016431 A2 WO2002016431 A2 WO 2002016431A2 DE 0103140 W DE0103140 W DE 0103140W WO 0216431 A2 WO0216431 A2 WO 0216431A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptides
- antibodies
- psoriasis
- adrenergic receptor
- amino acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 46
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 35
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 31
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 title abstract description 8
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 title abstract description 8
- 230000001575 pathological effect Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 6
- 230000000890 antigenic effect Effects 0.000 claims abstract description 5
- 230000002163 immunogen Effects 0.000 claims abstract description 4
- 238000001514 detection method Methods 0.000 claims description 17
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 150000001413 amino acids Chemical group 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 230000008030 elimination Effects 0.000 claims description 4
- 238000003379 elimination reaction Methods 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000013060 biological fluid Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000012876 carrier material Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000000053 physical method Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims 3
- 239000010839 body fluid Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 101710120037 Toxin CcdB Proteins 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 201000005857 malignant hypertension Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 19
- 108020003175 receptors Proteins 0.000 abstract description 19
- 238000003149 assay kit Methods 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract 1
- 238000004166 bioassay Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000000674 adrenergic antagonist Substances 0.000 description 2
- 230000002057 chronotropic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the invention relates to peptides of the ⁇ l-adrenergic receptor and their use and their derivatives in antigenic and immunogenic agents or test kits, in particular for the elimination of specifically binding, cell-physiologically active, pathological antibodies in psoriasis and for their diagnostic detection.
- the invention also relates to a method for the detection of anti- ⁇ l-adrenergic receptor antibodies in biological fluids.
- Psoriasis is a common skin disease, which causes severe dandruff, especially under certain triggering conditions (e.g. climate, mechanical irritation, metabolic disorders, etc.) due to increased proliferation of the epidermis. It occurs in episodes or chronically and occurs in 2% of the population. In addition to a genetic predisposition, an infectious or an autoimmune cause is discussed. So far it has been assumed that the cause of psoriasis is due to a disturbed immune response. The humoral component of the immune system also plays a crucial role in this disease. Psoriasis can occur at any age and has not yet been curable. A lifelong course can often be observed. The most common form is psoriasis vulgaris. In this form, there are inflammatory reddish areas covered with dandruff on the skin without disturbing the general condition.
- the object of the invention was to find substances which enable the detection of pathological antibodies and / or the treatment of psoriasis in psoriasis, and to provide them in corresponding medicaments and test kits. Another task is to enable the elimination of such antibodies from the blood.
- the invention is based on the first proof that patients with psoriasis have specific antibodies against ⁇ 1-adrenergic receptors.
- the observed ⁇ l-adrenergic receptor antibodies lead to an activation of the ⁇ l-adrenergic receptor, which is probably associated with peripheral vasoconstriction and mast cell granulation.
- Serum samples from patients with psoriasis contain autoantibodies that are directed against the ⁇ l-adrenergic receptor subtype. These antibodies develop a positive chronotropic effect in a bioassay. This effect is selectively blocked by the ⁇ l-adrenergic antagonist prazosin and neutralized by the peptide sequences described. It was surprisingly found that the antibodies recognize an epitope of the ⁇ 1-adrenergic receptor and that they can be neutralized or purified by affinity chromatography using peptides that correspond to this epitope.
- the epitope is characterized by the amino acid sequences LEVLGYWVLGRIFCD, GRIFCD of the ⁇ lB I-adrenergic receptor, by the sequences FWAFGRAFCDV, GRAFCDV of the ⁇ lA I-adrenergic receptor and by the sequences YWAFGRVFCNI, GRVFCNI of the ⁇ lDT-ADR gene and the sequence by the GRID-adrenergic receptor.
- an immunoglobulin fraction can be isolated from the plasma, which contains autoantibodies that bind to the ⁇ l-adrenergic receptor and activate the cell via it.
- the invention thus relates to peptides and their mutants and variants which recognize, bind and eliminate pathological autoantibodies from the plasma of patients with psoriasis.
- They are peptides that contain the physiologically active autoantibody-binding epitope of the ⁇ l-adrenergic receptor, as well as functionally analogous variants that form an epitope and can bind autoantibodies that occur in psoriasis.
- Peptides are preferred which are wholly or partially or as a variant of the sequences
- the peptides are synthesized according to methods known per se by building up the amino acids or are produced by genetic engineering.
- Antibodies according to the invention which are directed against the epitope of the ⁇ 1-adrenergic receptor are characterized in that they recognize these peptides. They preferably recognize the peptides of sequences No. 1 to No. 7 or their mutants and variants. They are produced according to methods known per se by immunizing small mammals or immunizing spleen cells in vitro with the peptides according to the invention.
- the antibodies are used in various bio-assays, immunological detection systems and ELIS A test systems.
- the invention relates to antigenic agents for the detection of psoriasis which contain at least one peptide according to the invention, preferably one or more peptides of numbers 1 to 7. They react with the specific antibodies against ⁇ l-adrenergic receptors that occur in psoriasis.
- the antigenic agents are bound to various carriers, e.g. activated Sepharose, cellulose or polystyrene carrier.
- peptides according to the invention are in immunogenic agents. These contain at least one peptide, preferably one or more peptides No. 1 to 6, which induces the production of antibodies which are able to recognize autoantigens in psoriasis.
- the invention also provides a test kit for the determination of ⁇ 1-adrenergic receptor antibodies for the detection of psoriasis.
- the test kit includes
- At least one peptide according to the invention optionally bound to a solid phase, a buffer
- the bio-assay includes
- the invention further relates to a method for the detection of ⁇ l-adrenergic receptor antibodies in biological fluids.
- the sample to be examined is brought into contact with at least one peptide according to the invention or with a compound of these peptides with a carrier material under conditions which permit an antigen-antibody reaction.
- the detection is then carried out using known chemical or physical methods.
- the anti- ⁇ l-adrenergic receptor antibodies could be detected in all sera examined so far from patients with psoriasis and are directed against the first extracellular loop of the ⁇ l-adrenergic receptor.
- the antibodies behave like hormones with an ⁇ l-adrenergic effect in in vitro tests, these antibodies play a role in the pathogenesis. Because they can be detected in all psoriasis sera examined, they are important as diagnostic markers.
- Cultivated neonatal rat heart cells were used as bioassay.
- the anti- ⁇ l adrenoceptor antibodies isolated from the serum induced an acceleration of the pulsation rate, which could be blocked by specific ⁇ l-adrenergic antagonists.
- the detection of these ⁇ 1-adrenergic receptor antibodies serves both for the early detection of psoriasis and as a basis for new types of therapy.
- the invention thus also relates to therapeutic agents against psoriasis which contain these peptides, since the removal of the ⁇ l-adrenergic receptor antibodies from the blood (for example by means of specific or non-specific immunoadsorption) leads to an improvement in the clinical picture or at least prevents progression can, which is associated with a reduction in symptoms and in particular with a significant improvement in the quality of life of the patients.
- the specific immunoadsorption is carried out on a column on which there are peptides in which at least the antibody-binding sequence of a peptide with the sequence No. 1-7 is contained.
- the non-specific immunoadsorption is carried out on a column, which is preferably sheep or. Chicken antibodies against the human immunoglobulins or protein A or Cl q or immunoglobulin binding peptides.
- the non-specific immune adsorption can be carried out with tryptophan columns. With this adsorber, all Ig of the blood plasma, including the autoantibodies directed against the ⁇ l-adrenergic receptor, are bound and eliminated using a suitable apparatus known to the person skilled in the art. Sepharose is preferably used as the column material for these adsorbers.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001285707A AU2001285707A1 (en) | 2000-08-24 | 2001-08-23 | Peptides of the alpha1-adrenergic receptor and their use for psoriasis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10041560.1 | 2000-08-24 | ||
DE10041560A DE10041560A1 (de) | 2000-08-24 | 2000-08-24 | Peptide des alpha1-adrenergen Rezeptors und ihre Verwendung bei Psoriasis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002016431A2 true WO2002016431A2 (de) | 2002-02-28 |
WO2002016431A3 WO2002016431A3 (de) | 2002-07-18 |
Family
ID=7653628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2001/003140 WO2002016431A2 (de) | 2000-08-24 | 2001-08-23 | PEPTIDE DES α1-ADRENERGEN REZEPTORS UND IHRE VERWENDUNG BEI PSORIASIS |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001285707A1 (de) |
DE (1) | DE10041560A1 (de) |
WO (1) | WO2002016431A2 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7741050B2 (en) | 2002-11-29 | 2010-06-22 | Max-Delbrueck-Centrum fuer Molkulare Medizin | Identification of agonistic autoantibodies |
WO2013023852A1 (en) * | 2011-08-12 | 2013-02-21 | E.R.D.E.-Aak-Diagnostik Gmbh | Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia |
EP2683826B1 (de) * | 2011-03-07 | 2016-06-08 | Charité Universitätsmedizin Berlin | Verwendung von aptameren zur behandlung und/oder diagnose von autoimmunerkrankungen |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19653669A1 (de) * | 1996-12-13 | 1998-06-18 | Affina Immuntechnik Gmbh | Adsorptionsmatrix, ihre Herstellung und ihre Verwendung zur Entfernung von Immunglobulinen aus biologischen Flüssigkeiten |
WO1999062933A2 (de) * | 1998-06-02 | 1999-12-09 | Affina Immuntechnik Gmbh | Rational designte peptide, ihre herstellung und ihre verwendung |
WO2001032853A1 (en) * | 1999-10-29 | 2001-05-10 | Institute For Applied Biomedicine | B cell clonal toxins and methods for using the same |
-
2000
- 2000-08-24 DE DE10041560A patent/DE10041560A1/de not_active Withdrawn
-
2001
- 2001-08-23 WO PCT/DE2001/003140 patent/WO2002016431A2/de active Application Filing
- 2001-08-23 AU AU2001285707A patent/AU2001285707A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19653669A1 (de) * | 1996-12-13 | 1998-06-18 | Affina Immuntechnik Gmbh | Adsorptionsmatrix, ihre Herstellung und ihre Verwendung zur Entfernung von Immunglobulinen aus biologischen Flüssigkeiten |
WO1999062933A2 (de) * | 1998-06-02 | 1999-12-09 | Affina Immuntechnik Gmbh | Rational designte peptide, ihre herstellung und ihre verwendung |
WO2001032853A1 (en) * | 1999-10-29 | 2001-05-10 | Institute For Applied Biomedicine | B cell clonal toxins and methods for using the same |
Non-Patent Citations (1)
Title |
---|
H.-P. LUTHER ET AL.: "Alpha1-adrenergic receptor antibodies in patients with primary hypertension" HYPERTENSION, Bd. 29, Nr. 2, 1997, Seiten 678-682, XP002197208 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7741050B2 (en) | 2002-11-29 | 2010-06-22 | Max-Delbrueck-Centrum fuer Molkulare Medizin | Identification of agonistic autoantibodies |
EP2683826B1 (de) * | 2011-03-07 | 2016-06-08 | Charité Universitätsmedizin Berlin | Verwendung von aptameren zur behandlung und/oder diagnose von autoimmunerkrankungen |
US9862953B2 (en) | 2011-03-07 | 2018-01-09 | Charite—Universtatsmedizin Berlin | Use of aptamers in therapy and/or diagnosis of autoimmune diseases |
WO2013023852A1 (en) * | 2011-08-12 | 2013-02-21 | E.R.D.E.-Aak-Diagnostik Gmbh | Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia |
US9708372B2 (en) | 2011-08-12 | 2017-07-18 | E.R.D.E.-Aak-Diagnostik Gmbh | Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer's and vascular dementia |
Also Published As
Publication number | Publication date |
---|---|
DE10041560A1 (de) | 2002-03-07 |
WO2002016431A3 (de) | 2002-07-18 |
AU2001285707A1 (en) | 2002-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0669001B1 (de) | Bestimmung von peptidmotiven auf mhc-molekülen | |
DE102005029845A1 (de) | Verfahren zur Diagnose von rheumatischen Erkrankungen | |
Houba | Immunopathology of nephropathies associated with malaria | |
EP0480440A1 (de) | Monoklonale Antikörper gegen Melanom | |
WO2000058005A2 (de) | Immunadsorber zur sepsistherapie | |
EP0937982B1 (de) | Diagnostikum und Therapeutikum zur Behandlung der autoimmunen Hepatitis | |
EP0124896B1 (de) | Verfahren zur Gewinnung von Viren bzw. Virusantigenen und deren Anwendung in Diagnose und Therapie (Impfstoff) | |
US5780298A (en) | DNA encoding the sn-RNP-A antigen and fragments thereof | |
DE3218312A1 (de) | Monoklonale antikoerper, hybridoma-zellklone, verfahren zu ihrer herstellung und ihre verwendung zur erkennung von brustkrebs und maligner lymphogranulomatose | |
Astaldi et al. | Effect of a human serum thymic factor on hydrocortisone‐treated thymocytes | |
DE3714634A1 (de) | Verfahren zur selektiven immunologischen bestimmung von intaktem prokollagen peptid (typ iii) und prokollagen (typ iii) in koerperfluessigkeiten und mittel zu dessen durchfuehrung | |
EP1570272A2 (de) | Bestimmung agonistischer autoantikörper | |
EP0955361A1 (de) | Monoklonale Antikörper gegen tumorassoziierte Antigene, Verfahren zu ihrer Herstelung sowie ihre Verwendung | |
JPH09501770A (ja) | 中枢神経系障害の検出及び治療方法 | |
WO2002016431A2 (de) | PEPTIDE DES α1-ADRENERGEN REZEPTORS UND IHRE VERWENDUNG BEI PSORIASIS | |
WO2000039154A2 (de) | Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie | |
EP0538266A1 (de) | Prozedur zum Nachweiss und Präparation von Anti-IgE-Autoantikörper und Verwendung dieser Antikörper als aktive Agenzien in diagnostischen und Therapeutischen Kompositionen | |
DE60033783T2 (de) | Regulatorische/entfaltende peptide von ezrin | |
DE19954305A1 (de) | Peptide des AT¶1¶-Rezeptors und ihre Verwendung, insbesondere für die Diagnostider Präeklampsie | |
JPS6118560B2 (de) | ||
DE3609271A1 (de) | Verfahren und reagenz zum nachweis von autoimmunerkrankungen, arzneimittel zur behandlung von autoimmunerkrankungen sowie hierzu geeignete antiparatypische antikoerper | |
DE60031963T2 (de) | Verfahren zum Nachweis von Multipler Sklerose oder einer Prädisposition für die Entwicklung von Multipler Sklerose in einer biologischen Probe | |
DE69839163T2 (de) | Methode zur Feststellung der therapeutischen Aktivität eines MBP-Fragments | |
DE3628718A1 (de) | Geloeste interleukin-2-rezeptoren als indikator fuer immunreaktionen und neoplasien | |
WO2002073209A2 (de) | Verfahren zur identifikation von immunreaktiven epitopen auf proteinen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |